Increased aquaglyceroporin 9 expression disrupts arsenic resistance in human lung cancer cells

Zhi-Feng Miao1, Eddy Essen Chang, Feng-Yuan Tsai

  • 1Laboratory of Molecular Toxicology, Division of Environmental Health and Occupational Medicine, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan.

Insights

Lung cancer cells exhibit resistance to arsenic (As2O3) due to variations in anti-oxidative systems and DNA repair. Increased aquaglyceroporin 9 (AQP9) expression enhances arsenic uptake, overcoming resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Toxicology

Background:

  • Chemotherapy resistance is a significant challenge in lung cancer treatment.
  • Understanding the mechanisms of arsenic resistance is crucial for developing effective therapies.

Purpose of the Study:

  • To investigate the underlying mechanisms of arsenic resistance in human lung cancer cells.
  • To identify potential molecular targets for overcoming arsenic resistance.

Main Methods:

  • Characterization of four lung cancer cell lines for cytotoxicity, arsenic transport, glutathione levels, and 8-hydroxy-2'-deoxyguanosine (8-OHdG) production.
  • Assessment of arsenic influx/efflux activity and its correlation with resistance.
  • Gene transfection to evaluate the role of aquaglyceroporin 9 (AQP9) in arsenic uptake and resistance.

Main Results:

  • Lung cancer cell lines displayed varying sensitivities to arsenic trioxide (As2O3), with IC50 values ranging from 11.8 microM (CL3) to approximately 100 microM (A549, H1299, H1355).
  • Arsenic influx/efflux rates were comparable across resistant and sensitive cell lines, suggesting other factors contribute to resistance.
  • Differences in intracellular glutathione levels and 8-OHdG production indicated variations in anti-oxidative and DNA repair capacities.
  • Overexpression of AQP9 significantly increased arsenic uptake and reversed arsenic resistance in A549 cells.

Conclusions:

  • Membrane transporters, particularly AQP9, play a critical role in arsenic uptake and the development of arsenic resistance in human lung cancer.
  • Variations in cellular anti-oxidative systems and DNA repair mechanisms also contribute to arsenic resistance.
  • Targeting membrane transporters like AQP9 presents a potential strategy to enhance the efficacy of arsenic-based therapies in lung cancer.

Related Concept Videos